Skip to main content

OVACE

Generic: SULFACETAMIDE SODIUM

Verified·Apr 23, 2026
Manufacturer
Mission Pharmacal
NDC
0178-0620
RxCUI
1006107
Route
TOPICAL
ICD-10 indication
L70.0

Affordability Check

How much will you actually pay for OVACE?

In 30 seconds, see every legitimate way to afford OVACE — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About OVACE

What is this medication? Ovace is a prescription topical medication used to treat several types of inflammatory skin conditions, most notably seborrheic dermatitis and dandruff. The active ingredient in this medication is sodium sulfacetamide, which is an antibacterial agent that belongs to the sulfonamide family. It works by stopping the growth of certain bacteria on the skin that can lead to irritation and infection, thereby helping to reduce redness, scaling, and itching in affected areas like the scalp or face. This medication is available in various forms such as washes, foams, and creams, making it versatile for different skin types and application sites. In addition to treating dermatitis, Ovace is frequently prescribed for the management of acne vulgaris, as it helps clear up blemishes by controlling bacterial proliferation. Users should follow their doctor's instructions carefully when applying the product to ensure that the medication effectively manages oily skin and prevents the recurrence of skin flakes or breakouts.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Not Publicly Available
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for OVACE. Official source: DailyMed (NLM) · Label effective Aug 13, 2025

Indications and usage
INDICATIONS: This product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.
Dosage and administration
DOSAGE AND ADMINISTRATION: Seborrheic dermatitis including seborrhea sicca - Shake well before using. Apply to affected areas twice daily (morning and evening), or as directed by your physician. Avoid contact with eyes or mucous membranes. Repeat application as described for eight to ten days. As the condition subsides, the interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of this product should be reinitiated as at the beginning of treatment. Secondary cutaneous bacterial infections - Shake well before using. Apply to affected areas twice daily for eight to ten days.
Contraindications
CONTRAINDICATIONS: This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.
Warnings
WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN.
Adverse reactions
ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.